Mark Boster / Los Angeles Times
DAVID E.I. PYOTT: Allergan Chief Executive David E.I. Pyott said the FDA review was routine and was met by scant concern among the small community of specialists who treat children with cerebral palsy. Only one called Allergan on Friday, he said. "There is no concern within the neurological community," Pyott said.